Development of a mechanism-based pharmacokinetic/pharmacodynamic model to characterize the thermoregulatory effects of serotonergic drugs in mice
暂无分享,去创建一个
D. Mager | A. Yu | S. Schmidt | Xi-ling Jiang | Hong-Wu Shen
[1] A. Yu,et al. Modification of 5-methoxy-N, N-dimethyltryptamine-induced hyperactivity by monoamine oxidase A inhibitor harmaline in mice and the underlying serotonergic mechanisms , 2016, Pharmacological reports : PR.
[2] A. Halberstadt. Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine , 2016, Pharmacology Biochemistry and Behavior.
[3] Hongbin Sun,et al. Current developments in pharmacological therapeutics for chronic constipation , 2015, Acta pharmaceutica Sinica. B.
[4] A. Yu,et al. Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors , 2015, Neuropharmacology.
[5] K. Rahmouni,et al. The brain and brown fat , 2014, Annals of medicine.
[6] S. Zorn,et al. Lu AF21934, a positive allosteric modulator of mGlu4 receptors, reduces the harmaline-induced hyperactivity but not tremor in rats , 2014, Neuropharmacology.
[7] John M. Johnson,et al. Cutaneous vasodilator and vasoconstrictor mechanisms in temperature regulation. , 2014, Comprehensive Physiology.
[8] Š. Alušík,et al. Serotonin syndrome. , 2014, Neuro endocrinology letters.
[9] R. Tyndale,et al. Potential role of CYP2D6 in the central nervous system , 2013, Xenobiotica; the fate of foreign compounds in biological systems.
[10] D. Mager,et al. Pharmacokinetic Interactions between Monoamine Oxidase A Inhibitor Harmaline and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status , 2013, Drug Metabolism and Disposition.
[11] E. Liebelt,et al. Recognizing Serotonin Toxicity in the Pediatric Emergency Department , 2012, Pediatric emergency care.
[12] R. Bruno,et al. Emerging psychoactive substance use among regular ecstasy users in Australia. , 2012, Drug and alcohol dependence.
[13] A. Bortolozzi,et al. Acute 5-HT1A autoreceptor knockdown increases antidepressant responses and serotonin release in stressful conditions , 2012, Psychopharmacology.
[14] D. E. Nichols,et al. Behavioral effects of α,α,β,β-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor , 2012, Psychopharmacology.
[15] M. Geyer,et al. Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice , 2011, Journal of psychopharmacology.
[16] J. C. Winter,et al. Stimulus control by 5-methoxy-N,N-dimethyltryptamine in wild-type and CYP2D6-humanized mice , 2011, Pharmacology Biochemistry and Behavior.
[17] Adam L. Halberstadt,et al. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens , 2011, Neuropharmacology.
[18] S. Morrison,et al. Central efferent pathways for cold‐defensive and febrile shivering , 2011, The Journal of physiology.
[19] Hong-Wu Shen,et al. Nonlinear Pharmacokinetics of 5-Methoxy-N,N-dimethyltryptamine in Mice , 2011, Drug Metabolism and Disposition.
[20] Jeremy Terrien,et al. Behavioral thermoregulation in mammals: a review. , 2011, Frontiers in bioscience.
[21] A. Yu,et al. Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics. , 2010, Biochemical pharmacology.
[22] P. Gillman. Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): a review. , 2010, Headache.
[23] A. Yu,et al. Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model. , 2009, Biochemical pharmacology.
[24] B. Olivier,et al. Pharmacological characterization of harmaline-induced tremor activity in mice. , 2009, European journal of pharmacology.
[25] M. Baumert,et al. Blockade of 5-HT2A receptors suppresses hyperthermic but not cardiovascular responses to psychosocial stress in rats , 2009, Neuroscience.
[26] M. Geyer,et al. Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors , 2008, Psychopharmacology.
[27] A. Yu. Indolealkylamines: Biotransformations and Potential Drug–Drug Interactions , 2008, The AAPS Journal.
[28] A. Yuruktumen,et al. Syrian rue tea: A recipe for disaster , 2008, Clinical toxicology.
[29] M. Zaretskaia,et al. 3,4-Methylenedioxymethamphetamine- and 8-Hydroxy-2-di-n-propylamino-tetralin-Induced Hypothermia: Role and Location of 5-Hydroxytryptamine 1A Receptors , 2007, Journal of Pharmacology and Experimental Therapeutics.
[30] C. Villalón,et al. Cardiovascular responses produced by 5-hydroxytriptamine:a pharmacological update on the receptors/mechanisms involved and therapeutic implications , 2007, Naunyn-Schmiedeberg's Archives of Pharmacology.
[31] Xiaoning Wang,et al. Nonlinear random effects mixture models: Maximum likelihood estimation via the EM algorithm , 2007, Comput. Stat. Data Anal..
[32] Henrik Madsen,et al. PKPD Model of Interleukin-21 Effects on Thermoregulation in Monkeys—Application and Evaluation of Stochastic Differential Equations , 2007, Pharmaceutical Research.
[33] Y. Ootsuka,et al. Thermogenesis in brown adipose tissue: Increase by 5-HT2A receptor activation and decrease by 5-HT1A receptor activation in conscious rats , 2006, Neuroscience Letters.
[34] D. Rusyniak,et al. Hyperthermic syndromes induced by toxins. , 2006, Clinics in laboratory medicine.
[35] L. Peletier,et al. A Pharmacodynamic Turnover Model Capturing Asymmetric Circadian Baselines of Body Temperature, Heart Rate and Blood Pressure in Rats: Challenges in Terms of Tolerance and Animal-handling Effects , 2005, Journal of Pharmacokinetics and Pharmacodynamics.
[36] B. Levine,et al. A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation. , 2005, Journal of analytical toxicology.
[37] Amy E. Miller,et al. Evaluation of Herbal Dietary Supplements Marketed on the Internet for Recreational Use , 2005, The Annals of pharmacotherapy.
[38] M. Tariq,et al. Exacerbation of harmaline-induced tremor by imipramine , 2005, Pharmacology Biochemistry and Behavior.
[39] Mats O Karlsson,et al. Pharmacokinetic/pharmacodynamic modelling in oncological drug development. , 2005, Basic & clinical pharmacology & toxicology.
[40] D. Murphy,et al. Evidence that 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-induced hyperthermia in rats is mediated by stimulation of 5-HT2A receptors , 2005, Psychopharmacology.
[41] T. Ullrich,et al. Role of the serotonin 5-HT2A receptor in the hyperlocomotive and hyperthermic effects of (+)-3,4-methylenedioxymethamphetamine , 2005, Psychopharmacology.
[42] P. Bonaventure,et al. 8-OH-DPAT acts on both 5-HT1A and 5-HT7 receptors to induce hypothermia in rodents. , 2004, European journal of pharmacology.
[43] L. Peletier,et al. Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of 5-HT1A Receptor Agonists: Estimation of in Vivo Affinity and Intrinsic Efficacy on Body Temperature in Rats , 2004, Journal of Pharmacology and Experimental Therapeutics.
[44] E. Boyer,et al. Monoamine Oxidase Inhibitor Poisoning Resulting from Internet Misinformation on Illicit Substances , 2004, Journal of toxicology. Clinical toxicology.
[45] W. Löscher,et al. Pharmacodynamic effects of serotonin (5-HT) receptor ligands in pigs: stimulation of 5-HT2 receptors induces malignant hyperthermia , 1990, Naunyn-Schmiedeberg's Archives of Pharmacology.
[46] D. Spencer,et al. Serotonin receptor subtype mediation of the interoceptive discriminative stimuli induced by 5-methoxy-N,N-dimethyltryptamine , 2004, Psychopharmacology.
[47] R. Glennon,et al. Binding of β-Carbolines at 5-HT2 serotonin receptors , 2003 .
[48] William J Jusko,et al. Diversity of mechanism-based pharmacodynamic models. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[49] Tommy Pattij,et al. Stress-induced hyperthermia and anxiety: pharmacological validation. , 2003, European journal of pharmacology.
[50] J. Idle,et al. The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. , 2001, Molecular pharmacology.
[51] P H van der Graaf,et al. A set-point model with oscillatory behavior predicts the time course of 8-OH-DPAT-induced hypothermia. , 2001, American journal of physiology. Regulatory, integrative and comparative physiology.
[52] J. Ott. Pharmepéna-Psychonautics: Human Intranasal, Sublingual and Oral Pharmacology of 5-Methoxy-N, N-Dimethyl-Tryptamine , 2001, Journal of psychoactive drugs.
[53] P. Salmi,et al. Evidence for functional interactions between 5-HT1A and 5-HT2A receptors in rat thermoregulatory mechanisms. , 1998, Pharmacology & toxicology.
[54] Kinzo Matsumoto,et al. Central serotonin level-dependent changes in body temperature following administration of tryptophan to pargyline- and harmaline-pretreated rats. , 1997, General pharmacology.
[55] B. Roth,et al. High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine2A receptors: evidence in favor of a modified ternary complex model. , 1997, The Journal of pharmacology and experimental therapeutics.
[56] R. Ramsay,et al. Inhibition of Monoamine Oxidase A by β-Carboline Derivatives , 1997 .
[57] D. Goldstein,et al. Stress-induced activation of the sympathetic nervous system. , 1987, Bailliere's clinical endocrinology and metabolism.